German chemicals maker Bayer has been ordered to pay up to $11 billion to resolve thousands of claims from US cancer patients.
It comes after claims its weed killer, Roundup, could cause non-Hodgkin lymphoma.
While the settlement could be appealed, Bayer says it marks "a decisive milestone" for the company.
Agrochemical maker Bayer will pay up to $US7.25 billion ($11 billion) over two decades to resolve thousands of claims from US cancer patients, who say the company should have warned people that its popular weed killer, Roundup, could cause lymphoma, according to a settlement approved by a US judge.
The nationwide settlement handed down on Friday in Missouri applies both to Roundup users who already are ill and those who become diagnosed with non-Hodgkin lymphoma in future years.
Participants could get an average of between $US10,000 ($15,000) and $US165,000, depending on how they used the product, how old they were when diagnosed and the severity of their illness.
For Germany-based Bayer, which denies that Roundup causes cancer, the settlement provides some financial certainty against mounting litigation costs that have led it to contemplate pulling the product from US agricultural markets.
Bayer has already changed the formula for its Roundup version sold to residential users.
In Australia, all class actions alleging Roundup caused cancer ended without compensation payouts.